Michael Gelband’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Michael Gelband’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$364K	Buy	+74,966	New	+$299K	﹤0.01%	1316
2023 Q3	–	Sell	-18,410	Closed	-$519K	–	2220
2023 Q2	$519K	Sell	18,410 -56,182	-75%	-$1.35M	﹤0.01%	1341
2023 Q1	$1.28M	Sell	74,592 -11,053	-13%	-$224K	0.01%	1053
2022 Q4	$1.73M	Sell	85,645 -72,324	-46%	-$1.56M	0.03%	712
2022 Q3	$3.42M	Buy	+157,969	New	+$4.32M	0.04%	542
2021 Q3	–	Sell	-5,300	Closed	-$282K	–	2730
2021 Q2	$282K	Buy	+5,300	New	+$284K	﹤0.01%	1779

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Michael Gelband's ZNTL Position: Q2 2026 in Review

Michael Gelband opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 74,966 shares worth $364K. The stake represents ﹤0.01% of the portfolio and ranks #1316 among its holdings. This is a return to the name: Michael Gelband previously reported a position in ZNTL as recently as Q2 2023.

Michael Gelband first reported a position in ZNTL in Q2 2021 and has held it in 6 quarters since. The position peaked at $3.42M in Q3 2022. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Michael Gelband held 74,966 shares of Zentalis Pharmaceuticals worth $364K as of Q2 2026.
Zentalis Pharmaceuticals was a new Michael Gelband position in Q2 2026.
Zentalis Pharmaceuticals made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1316 holding.
Michael Gelband first reported a position in Zentalis Pharmaceuticals in Q2 2021 and has held it in 6 quarters since.
Michael Gelband's Zentalis Pharmaceuticals position peaked at $3.42M in Q3 2022.
113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.